Value-based care and early palliative care are strategies to mitigate rising cancer treatment costs due to longer patient ...

Horsham: Johnson & Johnson has announced the U.S. Food and Drug Administration (FDA) has approved DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) as a single agent treatment for adult ...

Johnson & Johnson secures FDA approval for Darzalex Faspro as the first and only treatment for adults with high-risk smoldering multiple myeloma, supported by Phase III Aquila trial data showing a 51% ...

The FDA has approved daratumumab and hyaluronidase-fihj monotherapy as treatment for adults with high-risk smoldering ...

The FDA approves Johnson & Johnson's Darzalex Faspro for high-risk smoldering multiple myeloma and Caplyta as an add-on ...

The approval for HR-SMM was based on data from the phase 3 AQUILA study, which evaluated Darzalex Faspro in adults aged 31 years and older with HR-SMM.

Approval of J&J's Darzalex marks a milestone for high-risk sMM patients, but GlobalData analyst Biswajit Podder believes ...

Kimberly Alexander's caregiving experience revealed a lack of awareness and support for multiple myeloma, especially in the ...

Darzalex Faspro’s approval for smoldering multiple myeloma could allow for earlier intervention and reduce the risk of ...

The FDA has approved daratumumab and hyaluronidase (DARA SC; Darzalex Faspro, Janssen Biotech) for adults with high-risk smoldering multiple myeloma (SMM). The approval makes DARA SC, a subcutaneous ...

From chemotherapy to immunotherapy, medical science has rewritten the story of survival and hope for blood cancer patients in ...

The FDA has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) for the treatment of adult patients with high-risk ...